Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OPRA-HF: SZC to Optimize MRA Therapy in Heart Failure
NCT04789239Phase 2Active, not recruiting
- Start
- Sep 2021
- Primary completion
- Dec 2025
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
A Phase 2 trial of sodium zirconium cyclosilicate in hyperkalemia. Started Sep 2021; status: active, not recruiting.
02
Drugs
sodium zirconium cyclosilicate
03
Conditions
hyperkalemia
Beyond the preview
Go deeper on NCT04789239.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04789239.